ABVC BioPharma, Inc. (ABVC) Stock

ABVC BioPharma, Inc. (ABVC) is a Healthcare stock trading at $0.90 (as of 2026-08-21), with a market capitalization of $23.38M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company developing drugs and medical devices for unmet medical needs in the United States. Its development pipeline includes oncology, mental health, and ocular candidates (e.g., ABV-1501, ABV-1504, ABV-1505, ABV-1703, ABV-1702, ABV-1701), alongside a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing and BioFirst.

Understand ABVC BioPharma, Inc.: how it makes money

ABVC BioPharma develops clinical-stage biopharmaceutical drugs and medical devices, and it makes money (when it does) through licensing revenue and royalties on net sales rather than from ongoing product sales.

The profit model is primarily royalty and licensing driven, and right now licensing revenue is 0.0 while the company is still building its clinical pipeline, so operating results are dominated by development-stage costs rather than sales.

Revenue by segment (latest quarter)
Royalties$0.0B
Licensing$0.0B

Business quality (Weak): Revenue is minimal and the only operating metric provided is licensing revenue, so investors should expect performance to hinge on clinical progress turning into future commercial arrangements.

Bull case

  • Clinical pipeline with multiple programs at meaningful development stages: ABV-1501 is in Phase I/II for triple negative breast cancer, ABV-1504 completed Phase II for major depressive disorders, ABV-1505 is in Phase II for attention deficit hyperactivity disorder, and ABV-1703 completed Phase I for pancreatic cancer.
  • Some evidence of monetization via royalties: The company reports 'Maximum Royalties on Net Sales' of 0.01B.

Bear case

  • No licensing revenue in the latest quarter: Licensing Revenue is 0.0B for the period ended 2026-03-31, indicating limited current monetization from licensing agreements.
  • Operating losses are severe: Operating margin is -41765.5% for 2026-03-31, reflecting heavy costs relative to revenue.
  • Clinical-stage execution risk: Because the company is developing drugs and medical devices through clinical trials, future success and commercial payoff are uncertain until programs demonstrate results and translate into revenue-generating arrangements.
Valuation — source: SEC EDGAR (first-party)
Price$0.90
Market Cap$23.38M
Price / Book1.91
Price / Sales89.14
FCF Yield-32.7%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$296000.00
Net Margin-2671.8%
Revenue Growth (YoY)-96.4%
EPS Growth (YoY)-76.9%
Financial Health — source: SEC EDGAR
Altman Z-Score-4.66 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.0
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderVANGUARD GROUP INC ($613306.00)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOUttam Yashwant Patil
Employees16
CountryUS
IPO Date2009-12-22

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Atossa Therapeutics, Inc. (ATOS)
  • Aytu BioPharma, Inc. (AYTU)
  • Cellectar Biosciences, Inc. (CLRB)
  • TherapeuticsMD, Inc. (TXMD)
  • Allarity Therapeutics, Inc. (ALLR)
  • Cocrystal Pharma, Inc. (COCP)
  • Neuphoria Therapeutics Inc. (NEUP)
  • Celularity Inc. (CELU)
ABVC earnings history · ABVC institutional & insider holders · ABVC KPIs & operating metrics · ABVC financials · ABVC investor presentations & press releases · ABVC SEC filings · ABVC peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.